Cargando…

Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease

BACKGROUND: Perceived risks of hyperkalemia and acute renal insufficiency may limit use of mineralocorticoid receptor antagonist (MRA) therapy in patients with heart failure, especially those with diabetes mellitus or chronic kidney disease. METHODS AND RESULTS: Using clinical registry data linked t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Lauren B., Lippmann, Steven J., Greiner, Melissa A., Sharma, Abhinav, Kelly, Jacob P., Fonarow, Gregg C., Yancy, Clyde W., Heidenreich, Paul A., Hernandez, Adrian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779000/ https://www.ncbi.nlm.nih.gov/pubmed/29275368 http://dx.doi.org/10.1161/JAHA.117.006540

Ejemplares similares

Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure
por: Kelly, Jacob P., et al.
Publicado: (2019)

Impact of an Expanded Hospital Recognition Program for Heart Failure Quality of Care
por: Heidenreich, Paul A., et al.
Publicado: (2014)

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention
por: Khazanie, Prateeti, et al.
Publicado: (2015)

Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines—Heart Failure
por: Selvaraj, Senthil, et al.
Publicado: (2018)

Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed‐Methods Study
por: Dev, Sandesh, et al.
Publicado: (2016)

Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
por: Sharma, Abhinav, et al.
Publicado: (2019)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization
por: Laskey, Warren K., et al.
Publicado: (2015)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2021)

Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation Among Patients Hospitalized With Heart Failure
por: Thomas, Kevin L., et al.
Publicado: (2013)

Mineralocorticoid Receptor Antagonists in High‐Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease
por: Pitt, Bertram, et al.
Publicado: (2017)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

Short‐ and Long‐term Rehospitalization and Mortality for Heart Failure in 4 Racial/Ethnic Populations
por: Vivo, Rey P., et al.
Publicado: (2014)

Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines–Heart Failure Registry
por: Cunningham, Luke C., et al.
Publicado: (2021)

Comparative Effectiveness of Primary Prevention Implantable Cardioverter‐Defibrillators in Older Heart Failure Patients With Diabetes Mellitus
por: Sharma, Abhinav, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
por: Vizzardi, Enrico, et al.
Publicado: (2014)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022)

Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes
por: Goldstein, Sarah A., et al.
Publicado: (2018)

Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
por: Jadhav, Uday, et al.
Publicado: (2023)

Timing of Postdischarge Follow‐Up and Medication Adherence Among Patients With Heart Failure
por: Chang, Leslie L., et al.
Publicado: (2018)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis
por: Chen, Meng-Die, et al.
Publicado: (2016)

Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study
por: Bruno, Noemi, et al.
Publicado: (2018)

Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
por: Jonsson, Anna, et al.
Publicado: (2018)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
por: Abe, Takuro, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonists and Protection Against Cardiovascular Disease in Patients with Diabetes Mellitus
por: Shimabukuro, Michio
Publicado: (2023)

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction
por: Golwala, Harsh B., et al.
Publicado: (2013)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction
por: Kagami, Kazuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dqpqtb9pqapppq4e2l7k5nlagl